CSI Market
Sign In | Register

Merrimack Pharmaceuticals Inc (MACK) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access MACK Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Merrimack Pharmaceuticals Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2024)
3 Months 		(Dec 31 2023) (Sep 30 2023) (Jun 30 2023) (Mar 31 2023)
Operating Activities
Income200.93
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Gain Loss On Mark To Market On Preferred Stock Warrants-
Amortization Of Deferred Lease Benefits And Tax Incentives-
Gain Loss On Mark To Market On Preferred Stock Warrants Cash Flow Impact-
Gain Loss On Mark To Market On Preferred Stock Warrants Noncash-
Other Non Cash Operating Items-
Allocated Share Based Compensation Expense Including Non Employees0.05
Loss On Sale Of Property Plant And Equipment-
Income Tax Expense Benefit Intraperiod Tax Allocation-
Non Cash Activity Related To Discontinued Operations-
Deconsolidation Gain Or Loss Amount-
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest-
Gain On Sale Of In Process Research And Development Asset-
Amortization And Accretion On Marketable Securities-
Income taxes0.00
Gain (Loss) on Sale of Equity Investments0.00
Increase (Decrease) in Receivables0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.13
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.10
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.37
Discontinued operations-202.89
Net Cash flow from Operating Activities-1.31
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Short-term Investments3.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Proceeds From Sale Of In Progress Research And Development Asset-
Proceeds From Sale Of In Process Research And Development Asset-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Proceeds from Sale of Equity Method Investments0.00
Proceeds from Sales of Business, Affiliate and Productive Assets225.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities228.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.49
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Initial Public Offering Net Of Offering Costs Less Deferred Financing Costs Reclassified To Equity-
Proceeds From Issuance Of Convertible Preferred Stock Of Subsidiary-
Proceeds From Exercise Of Stock Option And Warrants-
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.49
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-1.31
Total Cash Flow228.17
4 historic quarters locked

Sign in to unlock the full Merrimack Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Merrimack Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-060478

Figures are derived from filed reports and may be restated. Historical data is subject to revision.